Monofree (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride, the active ingredient in Monofree, is a local anesthetic presented as a sterile ophthalmic solution for ocular use. It provides rapid, reversible numbing of the corneal and conjunctival surface for diagnostic examinations and minor surgical procedures in adult patients and is commonly employed in ophthalmology clinics across the European market.

GNH USA supplies Monofree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics for global distribution.

Oxybuprocaine Hydrochloride is a topical ocular anesthetic used to temporarily block sensation in the eye surface.

- Slit‑lamp examination: provides rapid numbness to facilitate comfortable corneal evaluation. - Foreign body removal: enables painless extraction of superficial ocular debris. - Laser ophthalmic procedures: offers short‑acting anesthesia for laser photocoagulation or refractive surgery.

Adverse reactions to ocular administration of Oxybuprocaine Hydrochloride are generally limited to the treated eye.

Common Side Effects: - Burning or stinging sensation on instillation. - Transient conjunctival redness. - Increased tearing. - Temporary blurred vision.

Serious or Rare Side Effects: - Corneal epithelial defect or ulceration. - Severe allergic reaction (anaphylaxis). - Endophthalmitis.

When using Monofree, clinicians should observe several safety measures to minimise risk.

- Allergy assessment: verify no known hypersensitivity to oxybuprocaine or related anesthetics. - Limit duration: avoid repeated applications beyond the recommended clinical interval. - Corneal health: do not use on compromised corneal epithelium or active infection. - Concomitant drugs: exercise caution when combined with other topical ocular anesthetics. - Systemic conditions: monitor patients with cardiac conduction disorders, although systemic absorption is minimal. - Store at controlled room temperature: keep below 25 °C, in the original container, protected from light and moisture.

Oxybuprocaine Hydrochloride may interact with other ophthalmic agents; awareness of potential interactions helps maintain safety.

Major Interactions (Avoid): - Other topical ocular anesthetics: additive neurotoxicity may increase corneal damage. - Anticholinergic eye drops: may exacerbate dry eye and delay healing.

Moderate Interactions (Monitor Closely): - Beta‑blocker ophthalmic solutions: monitor for potential additive effects on intra‑ocular pressure. - Steroid eye drops: assess for delayed epithelial recovery. - Systemic sodium channel blockers (e.g., antiarrhythmics): observe for any unexpected systemic effects, although unlikely.